Large-cap Health Care company Viatris has moved 1.9% so far today on a volume of 5,516,638, compared to its average of 8,897,576. In contrast, the S&P 500 index moved -0.0%.
Viatris trades -24.98% away from its average analyst target price of $14.11 per share. The 9 analysts following the stock have set target prices ranging from $9.0 to $35.0, and on average have given Viatris a rating of hold.
Anyone interested in buying VTRS should be aware of the facts below:
-
Viatris has moved -4.2% over the last year, and the S&P 500 logged a change of 22.9%
-
Based on its trailing earnings per share of 1.51, Viatris has a trailing 12 month Price to Earnings (P/E) ratio of 7.0 while the S&P 500 average is 15.97
-
VTRS has a forward P/E ratio of 3.8 based on its forward 12 month price to earnings (EPS) of $2.8 per share
-
The company has a price to earnings growth (PEG) ratio of -1.39 — a number near or below 1 signifying that Viatris is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 0.61 compared to its sector average of 4.08
-
Viatris Inc. operates as a healthcare company worldwide.
-
Based in Canonsburg, the company has 38,000 full time employees and a market cap of $12.7 Billion. Viatris currently returns an annual dividend yield of 4.6%.